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Abstract
Background: Y2 receptor signalling is known to be important in neuropeptide Y (NPY)-mediated effects on energy
homeostasis and bone physiology. Y2 receptors are located post-synaptically as well as acting as auto receptors on NPY-
expressing neurons, and the different roles of these two populations of Y2 receptors in the regulation of energy
homeostasis and body composition are unclear.
Methodology/Principal Findings: We thus generated two conditional knockout mouse models, Y2
lox/lox and NPYCre/
+;Y2
lox/lox, in which Y2 receptors can be selectively ablated either in the hypothalamus or specifically in hypothalamic NPY-
producing neurons of adult mice. Specific deletion of hypothalamic Y2 receptors increases food intake and body weight
compared to controls. Importantly, specific ablation of hypothalamic Y2 receptors on NPY-containing neurons results in a
significantly greater adiposity in female but not male mice, accompanied by increased hepatic triglyceride levels, decreased
expression of liver cartinine palmitoyltransferase (CPT1) and increased expression of muscle phosphorylated acetyl-CoA
carboxylase (ACC). While food intake, body weight, femur length, bone mineral content, density and cortical bone volume
and thickness are not significantly altered, trabecular bone volume and number were significantly increased by
hypothalamic Y2 deletion on NPY-expressing neurons. Interestingly, in situ hybridisation reveals increased NPY and
decreased proopiomelanocortin (POMC) mRNA expression in the arcuate nucleus of mice with hypothalamus-specific
deletion of Y2 receptors in NPY neurons, consistent with a negative feedback mechanism between NPY expression and Y2
receptors on NPY-ergic neurons.
Conclusions/Significance: Taken together these data demonstrate the anti-obesogenic role of Y2 receptors in the brain,
notably on NPY-ergic neurons, possibly via inhibition of NPY neurons and concomitant stimulation of POMC-expressing
neurons in the arcuate nucleus of the hypothalamus, reducing lipogenic pathways in liver and/or skeletal muscle in females.
These data also reveal as an anti-osteogenic effect of Y2 receptors on hypothalamic NPY-expressing neurons on trabecular
but not on cortical bone.
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Introduction
Neuropeptide Y (NPY), a 36-amino acid peptide, is widely
expressed in the central and peripheral nervous systems and is an
important regulator of numerous physiological processes, includ-
ing energy balance [1,2]. In the central nervous system, NPY is
present in regions such as the hypothalamus, cerebral cortex, brain
stem, striatum and limbic structures [3], with the highest
expression in the hypothalamic arcuate nucleus (Arc) [4]. Central
control of energy balance is predominantly a function of
hypothalamic pathways including key connections with the Arc.
The Arc is located at the base of hypothalamus, and has direct
access to circulating hormones due to a semi-permeable blood
brain barrier [5]. Therefore, neurons within the Arc are able to
respond rapidly to peripheral signals and then project broadly to
other brain regions to modulate energy balance [6]. Located
within the Arc are two major populations of neurons that are
known to regulate energy balance: orexigenic NPY/agouti-related
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(POMC)/cocaine and amphetamine-regulated transcript (CART)
neurons [7]. Activation of NPY/AGRP neurons leads to release of
NPY and AGRP, which stimulate appetite, fat storage and weight
gain [8]. This occurs in association with effects of NPY on Y1 or
Y5 receptors [9] and the ability of AGRP to antagonize
melanocortin 3/4 (MC3/4) receptors in the paraventricular
nucleus [8]. POMC/CART neurons produce alpha-melanocyte
stimulating hormone (a-MSH), which acts to inhibit food intake,
weight gain and energy balance by action on central MC3/4
receptors in the paraventricular nucleus [10]. In addition, NPY/
AGRP neurons contact and inhibit adjacent POMC/CART
neurons by releasing the inhibitory neurotransmitter gamma-
aminobutyric acid (GABA) [5,11]. NPY expression increases
under conditions of food deprivation, which contributes to an
increase in food intake and contributes subsequently to positive
energy balance [12,13,14,15]. Surprisingly, body weight and
adiposity were normal in NPY-deficient mice fed with normal
chow [16]. However, NPY deficiency does lead to attenuated
responses to fasting and a high fat diet, and it also attenuates
hyperphagia and the obesity syndrome of ob/ob mice [16,17].
Consistent with an important role of NPY in the regulation of
energy homeostasis, intracerebroventricular or hypothalamus-
specific administration of NPY to normal rodents leads to defects
characteristic of obesity, including hyperphagia, accelerated body
weight gain, hyperleptinemia, hypercorticosteronemia, hyperinsu-
linemia and increased adiposity [18,19,20,21]. More importantly,
all of these neuroendocrine and metabolic effects of central NPY
administration, notably increased adiposity, persist even when
NPY-induced hyperphagia is prevented by pair-feeding, indicating
that hyperphagia is not the only mechanism by which central NPY
increases adiposity [18,21].
NPY mediates its effects via a family of G protein-coupled
receptors known as Y1, Y2, Y4, Y5, and y6 [4], each with varying
distribution across central and peripheral tissues. Y2 receptors are
widely expressed in areas of the brain such as the hypothalamus,
hippocampus and brain stem [22,23], and the involvement of Y2
receptors in energy homeostasis was initially supported by the
demonstration that acute or chronic central administration of the
Y2-preferring agonist NPY13-36 to normal rats deceases overnight
feeding [24] and daily food intake [20]. Additionally, NPY13-36
has been shown to inhibit NPY release from rat hypothalamic
sections in vitro, and this effect can be blocked by the selective Y2
receptor antagonist BIIE0246 [25]. More importantly, the gut-
derived satiety peptide PYY3-36, released postprandially, reduces
food intake in humans and in rodents via activation of Y2
receptors in the Arc [5]. Additional major support for the
importance of Y2 receptors in the regulation of energy
homeostasis comes from germline Y2 receptor knockout mice,
which exhibit reduced adiposity [26]. Moreover, germline deletion
of Y2 receptors leads to a significant reduction in adiposity or body
weight and the type 2 diabetic syndrome of ob/ob mice, in the
absence of reductions in food intake [27,28]. Co-localization
studies provided further evidence of the possible role of Y2
receptors in the hypothalamus – particularly within the Arc – in
the regulation of energy homeostasis. Studies suggest that up to
80% of NPY-expressing neurons in the Arc are co-localized with
Y2 receptors, and Y2 receptors have therefore been postulated to
act as auto-receptors that modulate the synthesis and release of
NPY [7,28], in keeping with the effects of Y2 agonists on NPY
release from hypothalamic explants in vitro [25]. However, there is
no direct in vivo evidence that such ‘pre-synaptic’ Y2 receptors
mediate effects on NPY expression and secretion and subsequently
on energy homeostasis.
In addition to effects on energy regulation, lack of Y2 receptors,
notably hypothalamic Y2 signalling as in conditional hypothala-
mus-specific Y2 receptor deletion in mice, results in increased
cortical and trabecular (cancellous) bone mass [29,30,31],
suggesting a potential link between the central control of energy
homeostasis and bone homeostasis [32]. Site-specific overexpres-
sion of NPY in the hypothalamus of mice markedly reduced the
capacity of osteoblasts to produce bone [29,32]. Consistent with
this effect being mediated by hypothalamic Y2 receptors,
conditional deletion of Y2 receptors from the hypothalamus of
adult mice produced a generalized increase in osteoblast mineral
apposition rate, with no evidence of changes in the bone-
resorption indices of osteoclast surface or osteoclast number
[31]. Remarkably, mineral apposition rate in cancellous bone of
hypothalamus-specific Y2
2/2 mice was elevated 2-fold, in parallel
with similar changes in cancellous bone volume [31].
Given the clear involvement of Y2 receptors in the regulation of
energy homeostasis and bone mass, we investigated the effect of
selective deletion of hypothalamic Y2 receptors in these processes,
using a conditional Y2 receptor knockout mouse model (Y2
lox/lox
mice) in which Y2 receptors were selectively deleted from the
hypothalamus via adeno-associated viral Cre-recombinase delivery
[26]. Furthermore, to explore the specific role of hypothalamic Y2
receptors on NPY neurons in the regulation of energy homeostasis
and bone mass, we established a unique conditional NPY neuron-
specific Y2 receptor deficient mouse model: NPYCre/+;Y2
lox/lox,
in which Y2 receptors were ablated only in hypothalamic neurons
that express NPY via hypothalamic injection of doxycycline. Gene
deletion in both models was induced in adult animals, thereby
minimizing developmental influences.
Materials and Methods
Animals
Animal experiments were approved by the Garvan Institute/St
Vincent’s Hospital Animal Ethics Committee (Ethics No: HH
#08/01) and were conducted in accordance with relevant
guidelines and regulations. Mice were housed under conditions
of controlled temperature (22uC) with a 12h light, 12 h dark cycle
(lights on at 0700 h). Mice were fed a normal chow diet ad libitum
(8% calories from fat, 21% calories from protein, 71% calories
from carbohydrate, 2.6 kcal/g; Gordon’s Speciality Stock Feeds,
Yanderra, New South Wales, Australia). Water was available ad
libitum for all mice. Generation of the conditional Y2
lox/lox and
NPYCre mice was described previously [26,32,33].
Generation of adult-onset hypothalamus-specific Y2
receptor knockout model (Y2
hyp)
Region-specific Y2 receptor deletion was achieved in mice
containing Y2 floxed alleles by injection with Cre-recombinase
expressing recombinant adeno-associated viral (rAAV) vectors as
previously described [26,34]. In brief, 12-week-old Y2
lox/lox mice
were anesthetized with a single dose of ketamine/xylazine (100/
20 mg/kg, ip) (Mavlab, Slacks Creek, Queensland, Australia;
Ilium Veterinary Products, Smithfiend, New South Wales,
Australia) and placed on a Kopf stereotaxic frame (David Kopf
Instruments, Tulunga, CA, USA). One microliter of rAAV vector
containing either the Cre-recombinase gene or an empty cassette
(1610
14 genomic copies/ml) was injected bilaterally into the
hypothalamus at a rate of 0.1 ml/min using a 2-ml Hamilton
syringe attached to syringe infusion pump (World Precision
Instruments Inc, Walthan, MA, USA). The resultant mice were
referred to as Y2
hypKO mice and Y2
lox/loxmice, respectively. The
injection coordinates relative to bregma were: anterioposterior
NPY Neuron Y2R Energy Balance
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responding to the arcuate nucleus (Arc) [35]. Animals were kept
on a heating pad during surgery and until recovery.
Generation of conditional NPY neuron-specific Y2
receptor knockout model
The inducible, conditional NPY neuron specific Y2 receptor
knockout model (NPYCre/+;Y2
lox/lox mouse) was generated using
a knock-in strategy. In brief, a mouse was generated in which the
NPY gene was replace by a cassette containing the reverse
tetracycline transactivator (rtTA) gene, and Cre-recombinase (Cre)
under the control of a tetracycline responsive element (TRE). The
construct was designed such that the endogenous NPY promoter
drives expression of the rtTA gene, which in the absence of
doxycycline is unable to bind and activate the TRE element to
transcribe the Cre gene. It is only after the addition of doxycycline
that Cre is expressed. The resultant homozygous conditional NPY-
Cre-expressing transgenic mice on a mixed C57/BL6-129/SvJ
background were crossed with Y2
lox/lox mice on the same
background. Heterozygous offspring were crossed again to obtain
heterozygous NPYCre/+;Y2
lox/lox mice. In the presence of the
inducer doxycycline (Dox), Cre expression is induced, subsequent-
ly leading to excision of the loxP-flanked Y2 receptor gene and
resulting in Y2 receptor ablation only in NPY-containing neurons.
Adult-onset NPY neuron-specific Y2 receptor deletion was
achieved by injection of 2 mg of doxycycline (Sigma-Aldrich Pty
Ltd, Sydney, NSW, Australia) in 2 mL saline into the left lateral
cerebral ventricle of 10–12 week-old NPYCre/+;Y2
lox/lox mice.
The injection coordinates relative to bregma were: anterioposter-
ior 20.34 mm; mediolateral 61.0 mm; dorsoventral 22.5 mm,
corresponding to the left lateral cerebral ventricle [35]. Surgery
was carried out in the same manner as described in the previous
section. Two groups of control mice were used for these
experiments: NPYCre/+;Y2
lox/lox mice receiving central admin-
istration of saline, to control for possible effects of the knock-in
construct and intracerebroventricular injection, and wild type
mice treated with intracerebroventricular doxycycline, to control
for possible effects of central doxycycline injection per se.
DNA and RNA extraction and quantitative real-time PCR
Y2 receptor deletion was confirmed using genomic DNA
extracted from the hypothalamic region of the brain as previously
described [26]. In brief, genomic DNA was isolated from
hypothalamic blocks from Dox- and saline-injected mice. PCR
was performed with the following primers: Oligo A, 59-
AGCATCCAGAGAAGTGCAAC-39 and Oligo B, 59-TTAA-
CATCAGCTGGCCTAGC-39. This primer pair only produces a
PCR product, 250 base pairs long, from DNA in which the Y2-
receptor gene has been deleted. PCR conditions were 5 minutes
denaturation at 95uC followed by 35 cycles of 1 minute at 95uC, 1
minute at 61uC and 40 seconds at 72uC. Total RNA from the
hypothalamic region of NPYCre/+;Y2
lox/lox and NPYCre/
+;Y2
2/2 mice was isolated using TrizolH Reagent (Sigma, St
Louis, MO, USA) following the manufacturer’s protocol. The
quality and concentration of total RNA was measured by a
spectrophotometer (Nanodrop 1000, NanoDrop Technologies,
LLC, USA). One microgram (1 mg) of total RNA was reverse
transcribed into cDNA using the Superscript III First-Strand
Synthesis System (Invitrogen, Mount, Waverley, VIC, Australia).
Quantitative real-time PCR using primers for the Y2 receptor
gene was carried out on a LightCyclerH (LightCyclerH 480, Roche
Applied Science, Germany) using the SensiMix
TM Probe (Bioline
Australia Pty Ltd, Alexandria, NSW, Australia) following the
manufacturer’s instructions. Expression of the housekeeping gene,
ribosomal protein L13A (RPL-13A), was carried out in the same
manner and was used to normalize expression level of the Y2
receptor.
Determination of food intake and body weight
Mice were housed individually and body weight was measured
twice a week at the same time of day. At 15 weeks of age,
spontaneous daily food intake was measured over 3 consecutive
days in individually housed mice. Actual food intake was
calculated as the weight of pellets taken from the food hopper
minus the weight of food spilled in the cage. The weight of spilled
food per day was determined as the 24-h increase in weight of the
cage bedding, after removing all feces and air-drying to eliminate
weight changes due to urine and water bottle drips. The average
was used for statistical analysis. At 16 weeks of age, fasting-induced
food intake was carried out after fasting for 24 h at 900 h, then
determining food intake as described above at 2, 4, 8, 24, 48 and
72 hours after re-introduction of food. Body weight was tracked at
the same time each day before and up to 72 hours after the 24-
hour fast.
Rectal temperature measurements
At 14–15 weeks of age, body temperature was measured at
8:30–9:00 h with a rectal thermometer (Physitemp Instruments
Inc, Clifton, NJ, USA). Temperature readings were taken within
10 seconds of removing the mouse from its cage. Repeat readings
were taken from each mouse on 3 consecutive days, and the
average of the three readings was used for statistical analysis.
In situ hybridization and densitometry
Mice were culled as described below and 20 mm thick coronal
sections of fresh frozen brains were cut and thaw-mounted on
charged slides and stored at 220uC until use. For radioactive in
situ hybridisation, DNA oligonucleotides complementary to mouse
NPY (59-GAGGGTCAGTCCACACAGCCCCATTCGCTTG-
TTACCTAGCAT-39) and POMC (59-TGGCTGCTCTCCA-
GGCACCAGCTCCACACATCTATGGAGG-39) were labelled
with [
35S] thio-dATP (Amersham Biosciences, Little Chalfont,
Buckinghamshire, UK) using terminal deoxynucleotidyltransferase
(Roche, Mannheim, Germany). The expression levels of NPY and
POMC mRNA were evaluated by measuring silver grain densities
over individual neurons from photo-emulsion-dipped sections as
described previously [26]. Background labeling was uniform and
never exceeded 5% of specific signal.
Glucose tolerance test (GTT)
At 17 weeks of age, mice were fasted for 16 h before
intraperitoneal injection of a 10% D-glucose solution (1.0 g/kg).
Blood samples were obtained from the tail tip at the indicated
times, and glucose levels were measured using a glucometer
(AccuCheck II; Roche, New South Wales, Castle Hill, Australia).
Indirect calorimetry and determination of physical
activity
Oxygen consumption rate (Vo2) and carbon dioxide output
(VCO2) were measured using an open circuit eight-chamber
indirect calorimeter (Oxymax series; Columbus Instruments,
Columbus, OH, USA) with airflow of 0.6 L/min. Studies were
commenced after 24 h of acclimation to the metabolic chamber
(dimensions 20610612.5 cm). Vo2 and VCO2 were measured in
individual mice at 27-min intervals over a 24-h period under a
consistent environmental temperature of 22uC. The respiratory
exchange ratio (RER) was calculated as the quotient of VCO2/Vo2,
NPY Neuron Y2R Energy Balance
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the value of 0.7 representing pure fat oxidation [36,37]. Energy
expenditure was calculated as calorific value (CV) x Vo2, where
CV is 3.815+1.232 x RER [38]. During the calorimetry study,
mice had ad libitum access to food and water.
During calorimetry, relative physical activity over 24 h in mice
was also measured using a monitoring system from Columbus
Instruments that reports activity as sequential beam breaks on an
infrared grid. Cumulative ambulatory counts of X and Y
directions were summed for 1 h intervals.
Bone densitometry and body composition analysis and
microcomputed tomography (micro-CT)
Whole body bone mineral density (BMD), bone mineral content
(BMC) and fat and lean body mass were measured on mice ventral
side down at 15 weeks of age using dual-energy X-ray
absorptiometry (DXA; Lunar PIXImus2 mouse densitometer,
GE Medical Systems, Madison, WI, USA) as stipulated by the
manufacturer. Mice were anesthetized with isoflurane, scanned,
and BMD, BMC and total body fat and lean body mass were
determined using the program provided by the manufacturer. The
head and the tail of the animal were excluded from the analysis of
body composition. Whole femoral BMD and BMC were measured
in excised left femora. Femora were DXA scanned with tibiae
attached and the knee joint in flexion to ninety degrees to ensure
consistent placement and scan of the sagittal profile. Following
fixation, left femora were cleaned of muscle and analysed using
micro computed tomography (micro-CT) with a Skyscan 1174
scanner and associated analysis software (Skyscan, Aartselaar,
Belgium). During scanning, the femora were enclosed in a rigid
plastic tube filled with 70% ethanol and prevented from moving by
polystyrene packing at the proximal end. The X-ray source was set
at 50 kV and 800 mA. Scanning was carried out with a 0.5 mm
aluminum filter in place in order to reduce noise, and sharpening
was set to 40%. Image projections were acquired over an angular
range of 180u (angular step of 0.4u) with pixel size of 6.2 mm and
the exposure set to 3600 ms. The image slices were reconstructed
using NRecon (Skyscan’s volumetric reconstruction software),
which uses a modified Feldkamp algorithm. Reconstruction was
carried out with automated misalignment compensation for each
individual sample and the following settings for the whole study
samples: beam-hardening correction set to 30%, ring artifact
correction set to 5, smoothing set to 4, and the threshold for defect
pixel masking set to 10%. The reconstructed images were then
straightened using Dataviewer software (Skyscan). Trabecular
bone of the distal femur was selected for analysis by fitting a
1m m 61.5 mm elliptic region of interest in the center of the
femur, starting at 40 slices (0.25 mm) proximally from the growth
plate and extending a further 160 slices (0.99 mm) in the proximal
direction. Cortical bone was analysed in 150 slices (0.93 mm)
selected at 730 slices (4.53 mm) proximal from the growth plate.
Thresholding was applied to the images to segment the bone from
the background and the same threshold setting was used for all the
samples. The following 3-dimensional parameters were calculated:
trabecular bone volume as a percent of tissue volume, trabecular
number, trabecular thickness, cortical bone volume and cortical
bone thickness.
Western blotting
Liver and muscle samples taken from animals culled as described
below were homogenized in RIPA buffer (25 mM TrisNHCl
pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate,
0.1% SDS) supplemented with Complete Protease Inhibitor
Cocktail Tablets (Complete Mini, Roche Diagnostic, Mannheim,
Germany). After centrifugation, clear lysates were collected and
protein concentrations were measured using microplate spectro-
photometer (Spectramax Plus
384, Molecular Devices Inc., Silicon
Valley, CA, USA) using a reagent from Biorad (Biorad, Gladesville,
NSW, Australia). Equal amounts of tissue lysates (20 mg protein)
were resolved by SDS-PAGE and immunoblotted with antibodies
against liver and muscle carnitine palmitoyltransferase (CPT-1)
(SantaCruz Biotechnology,Santa Cruz,CA,USA), phosphorylated
acetyl-CoA carboxylase (p-ACC), fatty acid synthase (FAS) (Cell
Signaling, Beverly, MA, USA) and peroxisome proliferator-
activated receptor (PPAR) c coactivator (PGC)-1a (Calbiochem,
Merck Pty Ltd Kilsyth, VIC, Australia). Immunolabelled bands
were quantified by densitometry.
Tissue collection, serum hormone analysis and assay of
tissue triglyceride content
At the completion of each study, mice were culled by cervical
dislocation between 12:00–15:00 h, trunk blood was collected,
allowed to clot at room temperature, centrifuged, and resultant
sera were stored at 220uC for subsequent analysis as described
below. Brains were removed and immediately frozen on dry ice.
White adipose tissue (WAT) depots (right inguinal, right
retroperitoneal, reproductive (right ovarian or right epididymal
for female and male mice, respectively), and mesenteric), brown
adipose tissue (BAT), pancreas, liver, skeletal muscle (deeper layer
of quadriceps containing mostly red fibres), right kidney, heart and
right testis were collected, weighed and stored at 280uC for
further analysis. The weight of WAT depots were summed
together and expressed as total WAT weight, normalized as a
percentage of body weight.
Serum insulin levels were measured using a radioimmunoassay
kit (Linco Research, St Louis, MO, USA). Serum concentrations
of glucose, triglycerides and free fatty acid were determined with
colorimetric kits (Trace Scientific, Melbourne, Australia and
Sigma Diagnostic, St. Louis, MO). Serum, muscle and liver
triglyceride contents were determined using a colorimetric assay
kit (Triglycerides GPO-PAP; Roche Diagnostics, Indianapolis, IN,
USA) as previously described [39].
Statistical analysis
Results were assessed by factorial ANOVA. When there was a
significant overall effect or an interaction effect, Bonferroni post-
hoc tests were performed to identify differences using GraphPad
Prism 5 (Version 5.0a, GraphPad Software, Inc). For all statistical
analysis, a p-value ,0.05 was considered to be statistically
significant.
Results
Effect of hypothalamus-specific Y2 receptor deletion on
body weight, food intake and adiposity
In order to evaluate the role of hypothalamic Y2 receptors in
the regulation of energy balance, Y2 receptors were selectively
deleted from the hypothalamus by injection of a recombinant
adeno-associated viral vector expressing Cre-recombinase (rAAV-
Cre) into the hypothalamus of adult male Y2
lox/lox mice. The
deletion of hypothalamic Y2 receptor deletion was confirmed by in
situ hybridisation (Figure 1A). Compared to empty vector-injected
control mice (Figure 1A(a)), Y2 mRNA expression is significantly
reduced in the Arc of rAAV-Cre-injected Y2
hypKO mice
(Figure 1A(b)). Compared to Y2
lox/lox control mice, 24-hour
spontaneous food intake of Y2
hypKO mice was significantly
increased (Figure 1B). The two groups of mice were of similar
initial body weight, with no significant difference in body weight in
NPY Neuron Y2R Energy Balance
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day 13 onwards, Y2
hypKO mice gained significantly more weight
compared to controls (Figure 1C). Increased body weight and food
intake were associated with a trend towards increased mass of
dissected white adipose tissue depots (expressed as a percent of
body weight) upon completion of the study at 38 days after rAAV
injection. Indeed, the summed weight of white adipose tissue
depots was 1.6860.13 versus 2.0960.40 percent of body weight in
Y2
lox/lox control and Y2
hypKO mice, respectively (data are mean
6 SEM of 8 mice per group; p=0.15). There was no statistically
significant difference in relative weights of brown adipose tissue
depots between the two groups (0.22760.013 versus 0.21560.02
percent of body weight in Y2
lox/lox and Y2
hypKO mice,
respectively. Data are mean 6 SEM of 8 mice per group). The
other organ weights as a percent of body weight in Y2
hypKO mice
did not differ significantly from those in control mice (data not
shown). These data suggests that lack of hypothalamic Y2
receptors leads to positive energy balance characterized by
hyperphagia and increased body weight gain, which is consistent
with the known role of Y2 receptors as a mediator of PYY3-36-
induced satiety [5]. Another possible contributor to weight gain in
this model is the increased bone mass that has been reported in
response to hypothalamus-specific Y2 receptor deletion in mice
[31]. However, as total body bone mineral content represents less
than 2% of body weight, increases in bone mass are unlikely to
contribute significantly to an increase in overall body weight.
Generation of a conditional NPY neuron-specific Y2
receptor knockout model
The majority of hypothalamic Y2 receptors are expressed on
NPY-containing neurons [28]. Therefore, in order to examine
whether the observed anabolic effect of hypothalamic Y2 receptor
deletion was due to the absence of Y2 receptors on these neurons,
a conditional knockout mouse in which Y2 receptors were deleted
specifically from NPY-expressing neurons was generated using a
knock-in strategy which allows for an inducible approach. Firstly,
an NPY-Cre ‘knock in’ targeting vector was constructed
(Figure 2A), in which the coding exons of the NPY gene were
replaced with a cassette consisting of the tetracycline repressor
(tetR) gene, followed by an enhanced green fluorescent protein
(EGFP) gene in the opposite orientation, a neo cassette for
selection and a Cre gene under the control of the tetracycline
Figure 1. Hypothalamus-specific Y2 deletion increases food intake and body weight. (A) Marked reduction in Y2 receptor mRNA in the Arc
of male Y2
lox/lox mice – as detected by in situ hybridization – after injection of Cre-expressing adenovirus into the hypothalamus (Y2
hyp KO mice,
Figure A (b)) compared to that in male Y2
lox/lox mice (Figure A (a), scale bar 40 mm). Food intake (B) and body weight (C) in male Y2
hypKO mice
compared to that of Y2
lox/lox-empty vector-injected control mice. Values are means 6 SEM of 8 male mice per group. * p,0.05 versus Y2
lox/lox control
mice. Arc: Arcuate nucleus of the hypothalamus; 3V: third cerebral ventricle.
doi:10.1371/journal.pone.0011361.g001
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stop codon of the Cre gene and the start codon of the EGFP gene
were modified to contain loxP sites in the same orientation,
allowing for the generation of a Cre-EGFP fusion product for
colour detection after Cre-mediated excision of the intervening
sequence. The EGFP gene, missing a functional ATG, is unable to
produce a protein on its own. The inducible NPY neuron-specific
expression of the Cre gene is achieved by the fusion of the
initiation codon of the NPY gene with that of the tetR gene, thus
enabling the endogenous NPY promoter to drive the expression of
this regulatory protein (Figure 2A). The tetR gene product on its
own is inactive, and it is only after the addition of doxycycline
(Dox) that it gains activity as a transcription factor by binding and
activating the TRE promoter region and transcribing the
adjoining gene, in this case Cre [40]. Mice containing this
knock-in construct were generated using standard ES technology,
and the resultant mice were bred to homozygosity. Homozygous,
inducible NPY-driven Cre-EGFP-knock-in mice were then crossed
with homozygous Y2
lox/lox mice to generate heterozygous
NPYCre/+;Y2
lox/lox mice for use in the present study.
NPY neuron-specific Y2 receptor gene deletion
To examine the specific role of Y2 receptors on NPY-expressing
neurons in the brain, particularly in the hypothalamus, in the
regulation of energy balance, 12 week-old conditional NPYCre/
+;Y2
lox/lox mice were injected with Dox into the lateral cerebral
ventricle to induce selective deletion of Y2 receptors in these
neurons. To confirm deletion of the Y2 receptor gene, genomic
DNA was isolated from the hypothalamus and subjected to PCR
analysis. Primers that are only able to produce a 250 base pair (bp)
product once the Y2-receptor gene has been removed were used
(Figure 2B, 2C). No product was produced using DNA isolated
from the hypothalamus of saline-injected control mice, but the
injection of Dox directly into the brain resulted in successful
deletion of Y2 receptors (Figure 2C). Additional confirmation of
successful gene deletion was obtained by quantitative real-time
Figure 2. Schematic diagram of NPY-Cre-GFP knock-in strategy and confirmation of Y2 receptor deletion. (A) Conditional NPY neuron-
specific Y2 receptor knockout mice (NPYCre/+;Y2
lox/lox mice) were generated using a knock-in strategy. The inducible NPY neuron-specific expression
of the Cre gene is achieved by fusion of the initiation codon of the NPY gene with that of the tetR gene, enabling the endogenous NPY promoter to
drive the expression of this regulatory protein upon addition of doxycycline (Dox). (B) Schematic drawing of position of oligonucleotide primers
(Oligo A & B) used for PCR verification of Y2 receptor knockout. (C) Using genomic DNA extracted from the hypothalamus of NPYCre/+;Y2
lox/lox mice,
Oligos A and B produced a 250 base pair (bp) product from a Dox-injected mouse, demonstrating deletion of the Y2 receptor gene, but no product
was produced using DNA from a saline-injected control mouse. (D) Y2 receptor mRNA extracted from the hypothalamus of male NPYCre/+;Y2
2/2
mice was significantly reduced compared to that of saline-injected mice.
doi:10.1371/journal.pone.0011361.g002
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nucleus with no significant effects on body weight, spontaneous or fasting-induced food intake. (A, C) Bright-field photomicrographs of
coronal brain sections, including the Arc, obtained from saline-injected control and doxycycline (Dox)-injected male NPYCre/+;Y2
2/2 mice after in situ
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receptor mRNA expression in Dox-injected NPYCre/+;Y2
2/2
mice, as shown in Figure 2D. There was no induction of Cre
expression in non-brain tissues, as determined by PCR in the liver,
kidney, muscle and white adipose tissue (data not shown).
Altered expression of neuropeptides in the
hypothalamus of conditional NPY neuron-specific Y2 null
mice
The localisation of Y2 receptors on NPY-expressing neurons
suggests a potential role for Y2 as an auto-receptor regulating the
expression and release of NPY and other co-localized neurotrans-
mitters such as AGRP [25]. In order to explore the effect of NPY-
neuron-specific Y2 receptor knockout on hypothalamic neuro-
peptide expression, we investigated the mRNA levels of two
important neurotransmitters in the Arc by in situ hybridization.
Consistent with its reported role as an auto-receptor, the absence
of Y2 receptors on NPY-containing neurons leads to a significant
increase in NPY mRNA expression in the Arc, as seen in Dox-
injected mice compared to saline-injected control mice (Figure 3A,
3B). Interestingly, mRNA expression for proopiomelanocortin
(POMC), the precursor for the anorexigenic alpha melanocyte
stimulating hormone (a-MSH), expressed in neurons interacting
with NPY-ergic neurons in the Arc, is significantly down-regulated
in Dox-injected NPYCre/+;Y2
lox/lox mice compared to that in
saline-injected control mice (Figure 3C, 3D). This finding suggests
that altered NPY neuron function influences neighbouring POMC
neurons in the Arc. These results further confirm successful
deletion of Y2 receptors in our model, and more importantly they
demonstrate that deletion of Y2 receptors on NPY-ergic neurons
of adult mice has significant effects on hypothalamic NPY
and POMC expression, highlighting the functional existence of
a negative feedback mechanism between NPY and its Y2
auto-receptors.
Effect of conditional NPY neuron-specific Y2 receptor
deletion on food intake and body weight
Increased NPY and decreased POMC mRNA expression in the
hypothalamus suggested that deletion of Y2 receptors on NPY-
ergic neurons could alter food intake. Interestingly, in contrast to
the knockout mice in which Y2 receptors were selectively deleted
from the hypothalamus (Figure 1), 24-hour spontaneous food
intake (Figure 3E, 3F), food intake in response to 24-hour fasting
(Figure 3G, 3H), daily water intake and faecal output (Table 1)
were not different in NPYCre/+;Y2
lox/lox mice injected with
doxycycline (NPYCre/+;Y2
2/2) of either gender compared to
wild type controls injected with saline or doxycycline, or NPYCre/
+;Y2
lox/lox mice injected with saline. All groups of mice recovered
lost body weight in an equivalent manner after 24-hour fasting
(data not shown). Additionally, body weight gain monitored over
an 8-week period after intracerebroventricular injection was not
different in Dox-injected NPYCre/+;Y2
lox/lox mice versus saline-
injected NPYCre/+;Y2
lox/lox or wild type mice of either gender
(Figure 3I, 3J). Nasal-anal length was also not significantly different
between NPYCre/+;Y2
2/2 mice and NPYCre/+;Y2
lox/lox or wild
type control mice (data not shown).
Despite no changes in food intake, body weight or length
measured in the above studies, when male NPYCre/+;Y2
2/2
mice were analysed over a 2-day period in indirect calorimetry
cages, a significant increase in body weight was observed in these
mice compared to age-matched wild type and saline-injected
NPYCre/+;Y2
lox/lox control mice, which actually displayed a
decrease in body weight during this change in housing (Table 2).
While Dox injection per se had no significant effect on most of the
parameters investigated in this study, Dox-induced deletion of Y2
receptors on central NPY-ergic neurons in male mice is associated
with a trend to increased spontaneous food intake and a significant
decrease in rectal temperature, with no change in faecal output
(Table 2). This transient positive energy balance in male NPYCre/
+;Y2
-/- mice relative to controls occurs without any changes in
oxygen consumption, respiratory exchange ratio (RER), an index
of metabolic fuel selection, or physical activity (Table 2). Similarly
to males, female NPYCre/+;Y2
2/2 mice gained significantly
more weight compared to wild type or saline-injected NPYCre/
+;Y2
lox/lox control mice while in the indirect calorimetry chambers
(Table 2). In contrast to males, this transient positive weight gain is
accompanied by unaltered daily food intake, fecal output or rectal
temperature, but a significant increase in oxygen consumption,
notably in the light phase, with – as in male mice – no change in
hybridization for NPY and proopiomelanocortin (POMC) mRNA. Scale bar, 40 mm. (B, D) Quantification of mean labeling intensity of neurons from in
situ hybridization, given as percentage coverage of neuronal surface by silvergrains 6 SEM of 5 male mice per group. *: p,0.05 versus saline-injected
control mice. Arc: Arcuate nucleus of the hypothalamus; 3V: third cerebral ventricle. Spontaneous food intake (E, F), cumulative fasting-induced food
intake (G, H) and body weight (I, J) are not altered by NPY neuron-specific Y2 receptor deletion in the hypothalamus. Data are mean 6 SEM of 5 or
more mice per group.
doi:10.1371/journal.pone.0011361.g003
Table 1. Effect of deleting Y2 receptors from hypothalamic NPY-expressing neurons on body weight, feeding parameters, body
composition and glucose metabolism.
Parameters Female Male
Wild type NPYCre/+;Y2
lox/lox Wild type NPYCre/+;Y2
lox/lox
Saline (5) Dox(5) Saline (7) Dox(8) Saline (5) Dox(7) Saline (6) Dox(12)
Daily water intake (g) 4.6960.34 5.3460.31 5.3360.19 4.6260.46 5.4460.64 5.3660.55 4.5460.25 4.4360.19
Daily fecal output (g) 1.3060.12 1.260.06 1.0760.11 1.1660.13 1.3160.12 1.3660.10 1.3660.07 1.3560.10
Fasting serum glucose (um/L) 6.5360.74 6.5560.85 7.9060.80 6.3061.50* 9.6060.35 9.0160.16 5.7660.62 6.0660.67
Glucose area under curve (mmol/l/120 min) 1060643 10856108 1080636 906.86108 1328691 1247632 10736188 1067658
Values are means 6 SEM of 5–12 wild type or NPYCre/+;Y2
lox/lox mice injected into the hypothalamus with either saline or doxycyline (Dox), as indicated in parentheses.
*p,0.05 versus sex-matched NPYCre/+;Y2
lox/lox mice.
doi:10.1371/journal.pone.0011361.t001
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NPYCre/+;Y2
lox/lox control mice, female NPYCre/+;Y2
2/2 mice
exhibited a significantly lower level of physical activity (Table 2).
Taken together, these observations demonstrate that Y2 receptors
on NPY-ergic neurons are not involved in the regulation of body
weight or feeding behaviour under basal conditions or after food
deprivation, but they may be important regulators of aspects of
energy homeostasis controlling body weight under conditions such
as stress.
Sex-specific changes in body composition in NPY neuron
specific Y2 receptor null mice
To investigate the possibility that Y2 receptors on NPY
producing neurons influence body composition, Dox-induced
NPYCre/+;Y2
2/2 mice were compared with age-matched saline-
injected NPYCre/+;Y2
lox/lox control mice and saline- or Dox-
injected wild type mice. Female but not male wild type mice
injected with Dox showed a trend to reduced total fat mass
(expressed as a percent of body weight) (p=0.06) (Figure 4A, 4B).
However, compared to saline-injected NPYCre/+;Y2
lox/lox con-
trol mice, female but not male NPYCre/+;Y2
2/2 knockout mice
display a trend towards increased percent adiposity after Dox
injection (Figure 4A, 4B), suggesting that NPY neuron-specific Y2
receptor ablation increases relative fat mass in female mice. Two-
way ANOVA revealed a significant interaction effect between
genotype and treatment, indicating that genotype modified the
outcome of Dox treatment. To examine the effect of Y2 receptor
deletion per se, independent of the effect of Dox, the weights of
dissected WAT depots (expressed as a percent of body weight) in
NPYCre/+;Y2
2/2 mice were normalised to corresponding values
of Dox-injected wild type mice, and the results were compared to
that of saline-injected NPYCre/+;Y2
lox/lox mice relative to saline-
injected wild type mice. Thus, an anabolic effect of NPY neuron-
specific Y2 receptor deletion became apparent: summed fat
weights in female but not male NPYCre/+;Y2
2/2 mice were
significantly increased (Figure 4C, 4D). Whole body fat mass
measured by dual energy X-ray absorptiometry (DXA) showed a
similar pattern of change to that of dissected fat mass in female
mice (Figure 4E, 4G). Interestingly, there was an increase in whole
body fat mass (as determined by DXA) in male Dox-injected
NPYCre/+;Y2
2/2 mice compared to saline- or Dox-injected wild
type mice (Figure 4F), but when this effect was normalized for the
effect of Dox per se there was no significant effect of Y2 receptor
deletion on fat mass in male mice (Figure 4H). Lack of Y2
receptors on NPY expressing neurons does not influence whole
body lean mass in either gender (Figure 4I, 4J).
In line with increased adiposity as determined by dissected
white adipose tissue mass and DXA scans in females, we have also
demonstrated that lack of Y2 receptors on NPY neurons increases
Table 2. Effect of deleting Y2 receptors from hypothalamic NPY-expressing neurons on body weight change, feeding parameters,
rectal temperature, oxygen consumption (VO2), respiratory exchange ratio (RER) and physical activity as determined during
indirect calorimetry.
Parameters Female Male
WT NPYCre/+;Y2
lox/lox WT NPYCre/+;Y2
lox/lox
Saline (5) Dox (5) Saline (7) Dox (8) Saline (5) Dox (7) Saline (6) Dox (12)
Body weight
change (%
initial BW)
0.6560.86 20.6560.79
# 0.7460.27 2.1060.82 * 20.6460.46 20.2860.33 21.1860.61 1.19360.35 *
Daily food
intake (g)
4.5260.30 4.5760.05 4.4260.05 4.5660.16 4.7460.49 4.2960.10 4.7760.18 5.0460.22
Daily fecal
output (g)
0.8060.07 0.7560.09 1.3860.32 0.9860.13 0.9660.08 0.9360.06 1.1160.12 1.2260.08
Rectal
temperature (C)
37.5760.10 36.7860.17 36.7060.06 36.6760.13 36.8460.10 36.9360.14 36.7760.01 36.1660.02 *
VO2 (kcal/kg/hr)
24 hour 4635.656117.24 4480.136106.17 3855.996135.88 4148.8156147.0* 3680.47690.10 3665.75654.22 3385.74681.37 3616.89674.79
Light phase 4349.00681.34 4086.16698.36 3503.746186.44 3879.316157.69* 3400.00677.19 3370.87635.75 3135.426105.78 3338.28672.80
Dark phase 4921.846157.37 4874.106148.61 4208.256127.88 4418.326150.05 3960.586113.78 3960.65684.227 3636.06698.75 3895.50693.06
RER
24 hour 0.98760.020 0.99960.023 0.95460.019 0.98360.018 0.94360.008 0.95760.006 0.96560.018 0.97460.009
Light phase 0.95060.021 0.97360.027 0.91860.021 0.94760.026 0.89360.012 0.92260.010 0.93060.023 0.96160.015
Dark phase 1.02360.020 1.02660.027 0.99060.022 1.01960.011 0.99260.01 0.99160.008 1.00060.017 0.96160.009
Physical activ ity (ambulatory counts/hr)
24 hour 592.86138.2 738.86147.7 227.3662.1 161.6628.8 * 311.7636.1 325.0630.7 149.2615.6 185.3627.9
Light phase 241.8658.0 253.9636.7 62.6616.8 55.8610.7 128.4625.4 106.7619.2 54.7467.18 81.3612.4
Dark phase 943.86219.0 1223.86291.7 384.76111.3 267.4649.5 494.9659.1 543.3649.9 243.6624.8 289.4648.0
Values are means 6 SEM of 5–12 wild type or NPYCre/+;Y2
lox/lox mice injected into the hypothalamus with either saline or doxycyline (Dox). The number of mice in each
group is indicated in parentheses.
#p,0.05 versus sex-matched saline-injected WT mice.
*p,0.05 versus sex-matched saline-injected NPYCre/+;Y2
lox/lox mice. Body weight change is expressed as a percentage of initial body weight after 2 days in the indirect
calorimetry chambers.
doi:10.1371/journal.pone.0011361.t002
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hepatic steatosis in females is associated with decreased protein
expression (as determined by Western blotting) of carnitine
palmitoyltransferase (CPT1), a key rate-limiting transmembrane
enzyme controlling the entry of long chain fatty acid into
mitochondria for oxidation, in both liver and skeletal muscle of
female mice (Figure 5E, 5F). Moreover, the protein expression of
phosphorylated acetyl-CoA carboxylase (p-ACC), a key enzyme in
fatty acid synthesis, in the muscle but not liver was also up-
regulated in these female mice (Figure 5G, 5H). Expression of
protein for fatty acid synthase (FAS) in the liver was unchanged in
female knockout mice (Figure 5I) but the muscle protein
expression of peroxisome proliferator-activated receptor (PPAR)
c coactivator (PGC1a), a master regulator of oxidation in
mitochondria, was significantly increased in the skeletal muscle
of female NPYCre/+;Y2
2/2 mice compared to that of controls
(Figure 5J). Unlike the result in females, liver triglyceride content
in male NPY neuron specific Y2 receptor deficient mice was
markedly reduced (Figure 5B, 5D) in association with a trend
towards increased liver and muscle CPT1 protein expression
(Figure 5E, 5F) and no change in protein expression of liver or
muscle phosphorylated ACC, FAS or PGC1a (Figure 5). Taken
together, these findings suggest sex-specific involvement of Y2
receptors on NPY-expressing neurons in the regulation of energy
metabolism, particularly adiposity, which could be mediated by
changes in several key enzymes involved in lipolysis and
lipogenesis in liver and skeletal muscle.
Effect of NPY neuron specific Y2 receptor deletion on
glucose metabolism
Some factors that regulate energy homeostasis do so in
association with changes in glucose metabolism, even in the
absence of effect on body weight or food intake [18]. We therefore
investigated the effect of NPY neuron-specific Y2 receptor deletion
on whole body glucose metabolism by examining glucose
clearance during an intraperitoneal glucose tolerance test.
Compared with control mice, female but not male mice with
conditional NPY neuron-specific Y2 receptor deletion displayed
improved fasting glycemia (Table 1). The areas under the glucose
tolerance curves were not significantly different among groups
(Table 1). These data indicate that Y2 receptors on NPY-ergic
neurons are not directly involved in the regulation of glucose
homeostasis.
Effect of NPY neuron specific Y2 receptor deletion on
bone homeostasis
We previously showed that germline Y2 receptor deletion leads
to pronounced anabolic effects on cortical [30] as well as
trabecular (cancellous) bone mass [31], and that adult-onset
hypothalamus-specific Y2 receptor deletion leads to increased
cortical bone mass [30] and significant increases in trabecular
bone mass [31]. We therefore wanted to determine the
contribution of Y2 receptors specifically expressed on NPY
neurons to these processes. We thus measured whole body bone
mineral density (BMD), whole body bone mineral content
(BMC), isolated femur BMD and BMC and femur length in
both genotypes and genders by dual energy X-ray absorptiometry
(DXA, Table 3). There is no significant difference among
groups in any of the above-mentioned parameters. As cortical
bone is the predominant type of bone detected by DXA scans of
the whole body or of isolated femora, these data indicate that Y2
receptors on non-NPY expressing neurons in the hypothalamus do
not regulate cortical bone homeostasis. This finding is corrobo-
rated by the detailed structural analysis by microcomputed
tomography (micro-CT), which revealed no difference between
genotypes in the volume or thickness of cortical bone in the distal
femora (0.9160.02 mm
3 and 0.2260.005 mm in Dox- versus
0.9160.02 mm
3 and 0.2260.004 mm in saline-injected NPYCre/
+;Y2
lox/lox (data are means6SEM of 6–8 male mice per group).
Representative micro-CT scans of cortical bone are shown in
Figure 6A and 6C. In contrast to this lack of effect on cortical
bone, Y2 receptor deletion on hypothalamic NPY-expressing
neurons resulted in slight (1.2-fold) but significant increases in
trabecular bone volume and trabecular number as determined by
analysis of micro-CT scans (6.7260.15% of total tissue volume
and 1.3260.02 trabeculae per mm in Dox- versus 5.5860.46%
and 1.0960.09 trabeculae per mm in saline-injected NPYCre/
+;Y2
lox/lox (data are means 6 SEM of 6–8 male mice per group,
p=0.02 for both comparisons), with no change in trabecular
thickness (data not shown). These findings are illustrated by the
representative micro-CT scans in figures 6B and 6D. This results
indicates that Y2 receptors on NPY-expressing neurons in the
hypothalamus influence trabecular bone, albeit other Y2 receptors
probably contribute to the pronounced 2-fold increase in
trabecular bone volume that was observed in mice in which Y2
receptors were deleted in the hypothalamus [31].
Discussion
Y2 receptor signalling has been shown to be critical for the
regulation of both adipose tissue and bone homeostasis, with
germline knockout of Y2 receptors reducing adiposity and
increasing bone formation [26,27,30,31]. In the present study
we now demonstrate that hypothalamic Y2 receptor deletion in
adult mice results in sustained positive energy balance character-
ized by hyperphagia, increased body weight gain and a marked
trend towards increased fat accretion in white adipose tissue. In
this study we also generated a unique conditional NPY neuron-
specific Y2 receptor knockout model, which allows the first in vivo
studies of the within cell relationship between NPY production
and Y2 auto-receptor signalling, and their subsequent effect on
energy balance and bone homeostasis. We thus demonstrated that
adult-onset selective deletion of Y2 receptors from hypothalamic
NPY-expressing neurons leads to significant female-specific
increases in adiposity and hepatic steatosis in the absence of
changes in spontaneous or fasting-induced food intake or body
weight, as well as increased body weight in male and female mice
Figure 4. Effects of deleting Y2 receptors from hypothalamic NPY-expressing neurons on body composition in female and male
mice. (A, B) Total weight of dissected white adipose tissue (WAT) depots, expressed as a percent of body weight, in wild type or NPYCre/+;Y2
lox/lox
mice injected into the hypothalamus with either saline or doxycyline (Dox). (C, D) Total WAT weight of Dox-injected NPYCre/+;Y2
lox/lox mice relative to
that of Dox-injected wild type mice (black columns) versus saline-injected NPYCre/+;Y2
lox/lox mice relative to saline-injected wild type mice (open
column). (E, F) whole body fat mass (expressed as a percent of body weight), (G, H) whole body fat mass of Dox-injected NPYCre/+;Y2
lox/lox mice
relative to that of Dox-injected wild type mice (black columns) versus saline-injected NPYCre/+;Y2
lox/lox mice relative to saline-injected wild type mice
(open column). (I, J) whole body lean mass (expressed as a percent of body weight) of wild type or NPYCre/+;Y2
lox/lox mice injected into the
hypothalamus with either saline or doxycyline, as determined by dual energy X-ray absorptiometry (DXA). Data are mean 6 SEM of 5 or more mice
per group. *: p,0.05 for the comparison indicated by horizontal bar.
doi:10.1371/journal.pone.0011361.g004
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Importantly, we also showed that specific lack of Y2 receptor
signalling on hypothalamic NPY-expressing neurons leads to a
slight but significant increase in trabecular bone volume and
trabecular number, but is not critical for the regulation of glucose
metabolism or cortical bone homeostasis, suggesting a differential
role of Y2 receptors in the regulation of energy homeostasis and
cortical bone mass that is dependent on location.
Lack of Y2 receptors may cause net anabolic effects via removal
of presynaptic inhibition of NPY synthesis and inhibition on
POMC-expressing neurons. Consistent with this hypothesis,
deletion of Y2 receptors on hypothalamic NPY-ergic neurons
results in a significant increase in NPY mRNA levels in the Arc
compared to saline-injected control mice. For the first time, this
result provides direct in vivo evidence of a negative feedback
mechanism between NPY expression and Y2 auto-receptors.
Interestingly, besides an increase in NPY mRNA levels, POMC
mRNA levels are markedly down regulated in the Arc of mice
lacking Y2 receptors on NPY-expressing neurons. It is likely that
increased activity of NPY-ergic neurons enhances the inhibitory
effect of GABA-ergic neurotransmission to POMC neurons,
thereby decreasing POMC mRNA levels in the Arc [27,41]. This
hypothalamic profile of increased NPY and decreased POMC
expression is consistent with that seen in germline Y2 receptor
knockout mice, but is different from the overall hypothalamic Y2
receptor deletion model in which POMC mRNA levels are
increased, likely due to secondary adaptations [26]. These findings
suggest a catabolic role of Y2 receptors on NPY-ergic neurons,
and loss of these receptors in adult mice releases the inhibition on
NPY activity thereby leading to anabolic effects. Furthermore,
these data indicate that Y2 receptors on NPY neurons are
indirectly involved in the regulation of POMC mRNA levels in the
Arc, thereby exerting a further influence on energy balance.
This model of hypothalamic NPY neuron-selective Y2 receptor
deletion demonstrates increased white adipose tissue mass and
hepatic steatosis in female but not in male mice. There are a few
possible explanations for these findings. For instance, lack of PYY-
induced satiety [42] and PYY-induced catabolic effects [43] acting
via hypothalamic Y2 receptors may contribute to the elevated
adiposity [42] in female mice. Moreover, increased hypothalamic
NPY mRNA and decreased POMC mRNA may, at least in part,
contribute to a peripheral increase in adiposity and liver
triglyceride content in females. Previous studies have shown that
female rodents are more responsive than males to the obesogenic
effects of centrally-administered NPY [19]. In keeping with this,
germline and hypothalamus-specific Y2 receptor knockout also led
to differential effects on food intake, adiposity, serum pancreatic
peptide and corticosterone concentrations in male and female
mice [26]. It is likely that there exists an interaction between Y2
receptor signalling and sex steroid pathways in the regulation of
several processes involved in energy homeostasis. Indeed, germline
deletion of Y2 receptors prevents the elevation in WAT mass
following ovariectomy, and Y2 receptors other than those located
in the hypothalamus are most likely responsible for this effect [44].
Additionally, imbalances between lipolytic and lipogenic pathways
in the liver and skeletal muscles, two major metabolically active
tissues involved in energy homeostasis, may be underpinning the
sex-specific changes in triglyceride accumulation in these animals.
For example, CPT1 is the rate-limiting transmembrane enzyme
for the entry of long-chain fatty acids into mitochondria for b-
Figure 5. Effects of deleting Y2 receptors from hypothalamic NPY-expressing neurons on liver triglyceride content and expression
of key proteins regulating energy metabolism in female and male NPYCre/+;Y2
lox/lox mice and wild type mice. (A, B) Liver triglyceride
content in female and male wild type or NPYCre/+;Y2
lox/lox mice injected into the hypothalamus with either saline or doxycyline (Dox). (C, D) Liver
triglyceride content of Dox-injected NPYCre/+;Y2
lox/lox mice relative to that of Dox-injected wild type mice (black columns) versus saline-injected
NPYCre/+;Y2
lox/lox mice relative to saline-injected wild type mice (open columns). Protein levels (determined by Western blotting) of liver and muscle
carmitoyl palmitate transferase 1 (CPT1) (E, F), liver and muscle phosphorylated acetyl-CoA carboxylase (p-ACC) (G, H), liver fatty acid synthase (FAS) (I)
and muscle peroxisome proliferator-activated receptor (PPAR) c coactivator (PGC1a) (J) in female or male NPYCre/+;Y2
lox/lox mice treated with saline
or Dox. Data are means 6 SEM of 6–12 mice per group. *, p,0.05 for the comparison indicated by horizontal bars.
doi:10.1371/journal.pone.0011361.g005
Table 3. Effects of NPY neuron-specific Y2 receptor deletion on bone parameters determined by dual energy X-ray absorptiometry
(DXA).
Parameters Female Male
WT NPYCre/+;Y2
lox/lox WT NPYCre/+;Y2
lox/lox
Saline (5) Dox (5) Saline (7) Dox (8) Saline (5) Dox (7) Saline (6) Dox (12)
Whole body
BMD (g/mm
3)
0.04960.002 0.0560.003 0.05160.001 0.05260.001 0.05260.001 0.05360.001 0.05360.001 0.05460.001
Isolated femur
BMD (g/mm
3)
0.05660.002 0.05960.002 0.05860.002 0.0660.001 0.05760.002 0.05960.002 0.05660.001 0.05760.001
Whole body
BMC (g)
0.31360.029 0.32460.033 0.33460.021 0.35460.012 0.37260.022 0.39460.012 0.36960.007 0.38660.009
Isolated femur
BMC (g)
0.01960.001 0.02060.001 0.02160.001 0.02260.001 0.02460.001 0.02460.001 0.02460.001 0.02560.001
Femur length
(mm)
15.7660.36 15.9860.18 15.9160.20 15.8760.19 16.5760.19 16.6660.13 16.1460.18 16.1460.08
Whole body bone mineral density (BMD), bone mineral content (BMC) and isolated femur BMD and BMC were measured by DXA. Values are means 6 SEM of 5–12 mice
per group as shown in parentheses.
doi:10.1371/journal.pone.0011361.t003
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the trend towards increased expression of CPT1 in males)
highlights the sex-specific role of Y2 receptors on NPY neurons
in the control of fatty acid influx into mitochondria for oxidation
in the liver and skeletal muscle. Additionally, biosynthesis of fatty
acid is likely, at least in part, to also be regulated by NPY neuron
specific Y2 signalling, as evident by altered expression levels of
acetyl-CoA carboxylase (ACC) in skeletal muscle of female mice,
which could subsequently inversely influence expression of CPT1.
Despite the significant alterations in fat mass and hepatic
triglyceride levels in female hypothalamic NPY neuron-specific Y2
deficient mice, feeding behaviour and body weight were not
altered in male or female knockouts, although significantly
increased NPY and decreased POMC mRNA levels in the Arc
would have been predicted to induce hyperphagia and weight
gain. However, changes in adipose tissue depot weights are not
always associated with commensurate changes in body weight or
food intake in experimental animals [45,46]. Moreover, the Y2
receptor deletion-induced increase in hypothalamic NPY expres-
sion levels may not necessarily induce feeding responses, consistent
with findings from NPY knockout mice [16]. The orexigenic effect
of NPY is mediated via other receptors besides Y2, notably Y1
receptors, because hyperphagia is significantly reduced in Y1
receptor-deficient ob/ob mice [47]. Importantly, studies have
shown that a proportion of Y2 receptors are expressed on non-
NPY containing neurons in the Arc [28], and therefore the lack of
effect of NPY neuron-specific Y2 receptor deletion on feeding may
be due to the complex multiple effects of Y2 receptors.
Interestingly, the anti-obesogenic effects of germline Y2 receptor
knockout [26,27,48] were opposite to the lipogenic effects of
hypothalamus-specific Y2 receptor knockout or hypothalamic NPY
neuron-specific Y2 deletion demonstrated in this study. This finding
indicates mediation of an anti-obesogenic effect by Y2 receptors
other than those hypothalamicY2 receptors that were deleted in the
present study. Selective Y2 receptor deletion in peripheral tissues
would enable us to understand the roleof peripheralY2 receptors in
theregulationofboneandadiposetissue.ThewideexpressionofY2
receptors in peripheral tissues, including adipose tissue and the
pancreas [49], highlights the potential role of peripheral Y2
signalling in the regulation of energy homeostasis.
Deletion of Y2 receptors specificallyin the basolateraland central
amygdala induces anxiolytic effects [50]. Although our Y2 receptor
knockout strategy targeted Y2 receptors on NPY-expressing
neurons in the hypothalamus, we cannot exclude the possibility
that other populations of Y2 receptors on NPY-expressing neurons
(such as in the amygdala) were also deleted, which could have
contributed to reduced stress responses and thus the increased
adiposity observed in female mice lacking Y2 receptors on NPY-
expressing neurons, and also to the increased body weight observed
in both female and male knockouts in the novel environment of
indirect calorimetry cages, since novel stressors are known to induce
weight loss in rodents [27,51,52,53]. Y2 receptors are known to
regulate stress responses as well as activity of the hypothalamo-
pituitary adrenal axis, with germline Y2 receptor ablation reducing
anxiety [49,54,55,56] and decreasing hypothalamic expression of
corticotropin releasing hormone and the circulating concentrations
of corticosterone in lean or obese (ob/ob or diet-induced obese) mice
[27,57]. The present findings suggest that NPY neuron-specific Y2
receptors in the brain may mediate these effects of germline Y2
receptor ablation, and further studies dedicated to elucidating stress
responses in NPYCre/+;Y2
2/2 mice in the regulation of energy
balance are warranted.
Importantly, our data reveal that hypothalamic NPY neuron
specific Y2 receptor knockout has significant effects on trabecular
bone homeostasis, as evident from significant increases in trabecular
bone volume and trabecular number in femora from knockout
versus control mice. Because the magnitude of these changes was
not as great as the marked increase in these parameters observed in
response to overall Y2 receptor knockout in the hypothalamus of
adult mice [31], Y2 receptors on non-NPY-ergic neurons must play
a key role in the hypothalamic regulation of trabecular bone
homeostasis. In contrast, we saw that Y2 ablation on NPY-
expressing neurons in the hypothalamus has no effect on cortical
bone homeostasis,asindicatedbyunalteredbone mineraldensity or
bone mineral content in these conditional Y2 knockout mice of
either gender and no change in cortical volume or thickness. This is
in contrast to the increased cortical bone mass observed in germline
and hypothalamus-specific Y2 receptor deficient mice [30,31]. One
possibility for this discrepancy could be that parallel Y2 receptor-
activated pathways in the hypothalamus are responsible for cortical
bone regulatory functions, and effects of lack of Y2 receptors only in
NPY-ergic neurons might be compensated for by another Y2
receptor pathway. Taken together, these findings highlight the
Figure 6. Effects of deleting Y2 receptors from hypothalamic
NPY-expressing neurons on femoral morphology in saline-
injected (control) versus Dox-injected (knockout) NPYCre/
+;Y2
lox/lox mice. (A, C) Cross sectional microcomputed tomography
(micro-CT) images of the cortical bone of representative male NPYCre/
+;Y2
lox/lox mice injected into the hypothalamus with either saline or
doxycyline (Dox). (B, D) cross-sectional micro-CT images of trabecular
bone in the distal femora of male saline- or Dox-injected NPYCre/
+;Y2
lox/lox mice. Images are representative of 6–8 male mice per group.
Bar represents 0.2 mm.
doi:10.1371/journal.pone.0011361.g006
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receptors on non-NPY neurons in the regulation of bone mass and
energy metabolism.
In summary, we generated an adult-onset conditional NPY
neuron-specific Y2 receptor knockout model that has enabled us to
investigate the role of Y2 receptors specifically on hypothalamic
NPY-expressing neurons in the control of adipose tissue and bone
homeostasis. This study revealed no direct role of this type of Y2
receptor in cortical skeletal regulation, and it also provides clear
evidence of sex-specific functions in the regulation of trabecular
bone mass, adiposity and hepatic triglyceride accumulation, and
that these effects are achieved in association with changes in the
balance between lipogenic signalling pathways and lipolytic
signalling pathways in the liver and skeletal muscle, as summarized
in Figure 7. More importantly, this study has shown for the first
time the direct relationship between NPY production and Y2
auto-receptors in the Arc in vivo (Figure 7). The results of this study
suggest that enhancing the catabolic effect of NPY-ergic Y2
receptors may open up potential new ways to treat obesity without
any adverse effects on cortical bone mass, the major determinant
of bone strength.
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